The US Food and Drug Administration has approved Shire Plc’s new drug for acute attacks of hereditary angioedema, Firazyr (icatibant), the third treatment to be approved by the US regulator for this disease. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy